培美曲塞单药或联合铂类化疗治疗晚期甲状腺癌
该回顾性队列研究评估了培美曲塞单药或联合卡铂治疗晚期放射性碘难治性分化型及未分化甲状腺癌的疗效。22例患者(11例为未分化癌)接受培美曲塞作为四线治疗,中位治疗约5个月,部分缓解率27%,非未分化癌患者为45%。中位无进展生存期全组148天,非未分化癌患者375天。结论认为其疗效与已批准的二线治疗相当,需前瞻性试验证实。
要点
- 培美曲塞单药或联合卡铂在晚期甲状腺癌四线治疗中部分缓解率达27%。
- 非未分化甲状腺癌患者部分缓解率更高,达45%。
- 中位无进展生存期全组148天,非未分化癌患者375天。
核心结论
- 培美曲塞单药或联合卡铂对晚期甲状腺癌的疗效与已批准的二线治疗相当。
主要发现
- 22例患者中11例为未分化甲状腺癌,68%为女性,95%有远处转移,培美曲塞作为四线治疗中位 duration 约5个月。
- 从诊断到培美曲塞开始的中位时间为73个月。
- 全组部分缓解率为6/22(27%),非未分化甲状腺癌患者为5/11(45%)。
- 全组中位无进展生存期为148天,非未分化甲状腺癌患者为375天。
- 1例未分化甲状腺癌患者仍在接受培美曲塞/卡铂治疗且维持部分缓解。
临床怎么用
- 对于多线治疗后的晚期放射性碘难治性甲状腺癌,可考虑培美曲塞单药或联合卡铂作为挽救治疗。
局限性
- 回顾性研究设计,样本量小(22例),需前瞻性II期和III期临床试验确认疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Mortality from thyroid cancer is driven by advanced forms of the disease. While second-line therapies have been approved and recognized in thyroid cancer guidelines, development of toxicity and resistance requires addition of salvage treatments. METHODS: This retrospective cohort study evaluates the utility of pemetrexed as single agent or in combination with carboplatin for advanced radioiodine refractory differentiated and anaplastic thyroid cancer (ATC) treated at Memorial Sloan Kettering Cancer Center between December, 2023, and December, 2025. Our primary outcome was best overall response, and secondary outcomes were progression-free survival and disease-specific survival. RESULTS: Twenty-two patients (11 with ATC), 68% females, and 95% with distant metastatic disease, received pemetrexed single agent or in combination with carboplatin as a fourth-line therapy for a median duration of about 5 months. Median time to pemetrexed initiation was 73 months. Partial response (PR) was observed in 6/22 (27%) of all patients and in 5/11 (45%) with non-ATC. Median progression-free survival was 148 days for all tumors and 375 days for patients with non-ATC. One patient with ATC remains on pemetrexed/carboplatin with a PR to therapy. CONCLUSIONS: Pemetrexed single agent or in combination with carboplatin has comparable efficacy to approved second-line therapies for advanced thyroid cancer. Prospective Phase II and III clinical trials are needed to confirm the efficacy of this salvage therapy.
引用
- Boucai L, Fano R, Sherman EJ, et al. The Treatment of Advanced Thyroid Cancer Using Pemetrexed Monotherapy or with Platinum-Based Chemotherapy. Thyroid. 2026. PMID: 42524888. doi:10.1177/10507256261472631
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。